IS TIGECYCLINE EFFECTIVE IN CONTINUOUS AMBULATORY PERITONEAL DIALYSIS RELATED PERITONITIS

Basit Öğe Kaydı
dc.authoridOzden, Mehmet/0000-0002-1202-0864;
dc.authorwosidOzden, Mehmet/ABI-5449-2020
dc.authorwosidDogukan, Ayhan/W-2518-2018
dc.authorwosidDemirdag, Kutbeddin/W-6168-2018
dc.authorwosidTARTAR, Ayşe SAĞMAK/W-6397-2018
dc.contributor.authorTartar, Ayse Sagmak
dc.contributor.authorOzden, Mehmet
dc.contributor.authorDogukan, Ayhan
dc.contributor.authorAkbulut, Ayhan
dc.contributor.authorDemirdag, Kutbeddin
dc.contributor.authorTartar, Tugay
dc.date.accessioned2024-08-04T20:59:47Z
dc.date.available2024-08-04T20:59:47Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: To compare conventional intraperitoneal vancomycin-amikacin and intravenous tigecycline treatments for continuous ambulatory peritoneal dialysis (CAPD) related peritonitis. Materials and methods: Patients diagnosed with CAPD-related peritonitis were randomized into two groups as intravenous tigecycline group (n = 10) and intraperitoneal vancomycin-amikacin group (n = 20). Patients accompanied by peritonitis exit site infection, peritonitis based on Pseudomonas or fungi were excluded from the study. Results: As for 24th and 48th hours peritoneal fluid leukocyte count of patients, significant difference was not observed in tigecycline group at 24th hours, while significant reduction was observed in vancomycin-amikacin group (p < 0.05). A significant reduction was observed at 48th hours in both groups. As for the treatment response, abdominal pain decreased in 18 (90%) patients in vancomycin-amikacin group, decreased in 8 (80%) patients in tigecycline group at 48th hours. It was detected that dialysate leukocyte count decreased significantly (p > 0.05). Relapse was observed in 4 (40%) patients in tigecycline group, while not observed in vancomycin-amikacin group (p < 0.05). Conclusion: Tigecycline proved its effectiveness in the clinical use for complicated intra-abdominal infections. However, it was considered that tigecycline cannot be alternative to vancomycin-amikacin treatment for continuous ambulatory peritoneal dialysis related peritonitis.en_US
dc.identifier.doi10.19193/0393-6384_2017_4_104
dc.identifier.endpage705en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue4en_US
dc.identifier.startpage699en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2017_4_104
dc.identifier.urihttps://hdl.handle.net/11616/103534
dc.identifier.volume33en_US
dc.identifier.wosWOS:000403079700025en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTigecyclineen_US
dc.subjectvancomycinen_US
dc.subjectcontinuous ambulatory peritoneal dialysisen_US
dc.subjectperitonitisen_US
dc.titleIS TIGECYCLINE EFFECTIVE IN CONTINUOUS AMBULATORY PERITONEAL DIALYSIS RELATED PERITONITISen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu